ArticleThe Lancet regional health. Western Pacific2020
Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study.
Article in The Lancet regional health. Western Pacific, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 5 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Health economic evaluations of myasthenia gravis: a systematic review.Croatian medical journal · 2026Pooled it
- Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis.European journal of neurology · 2025Pooled it
- Effects of respiratory muscle training on respiratory function and functional outcomes in patients with myasthenia gravis: a systematic review.Frontiers in neurology · 2025Pooled it
- Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis.Orphanet journal of rare diseases · 2022Pooled it
- Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.Orphanet journal of rare diseases · 2021Pooled it
- Review
- Associations of Weight and Glucose Levels With Myasthenia Gravis: A Two-Step, Two-Sample Mendelian Randomization and Retrospective Case-Control Study.Brain and behavior · 2026Article
- Patient- and Caregiver-Reported Burden and Quality of Life in Generalised Myasthenia Gravis: A Multinational Real-World Survey in the Asia-Pacific Region.Neurology and therapy · 2026Article
- Ginsenoside Rg1 ameliorates experimental autoimmune myasthenia gravis by regulating T cell subsets, inhibiting PI3K-AKT pathway and modulating gut microbiota and metabolites.Journal of ginseng research · 2026Article
- Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.Journal of neurology · 2026Review
- Trends in hospitalisation, myasthenic crisis and intensive care use in myasthenia gravis: a nationwide population-based study in Spain (2016-2022).Neurological research and practice · 2026Article
- Current status and challenges of biologic targeted therapy for myasthenia gravis in China.Intractable & rare diseases research · 2026Review
- Successful prehospital resuscitation of a young female patient with myasthenia gravis experiencing cardiopulmonary arrest due to complete airway obstruction: a case report and review of the literature.Journal of medical case reports · 2026Review
- Monocyte-macrophage SAMHD1 alleviates EAMG by modulating the cGAS-STING pathway.Journal of neuroinflammation · 2026Article
- Social support in Chinese patients with myasthenia gravis and analysis of related factors: a cross-sectional study.BMC neurology · 2026Article
- Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report.Frontiers in immunology · 2026Article
- Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China.Frontiers in immunology · 2026Article
- Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort.PloS one · 2026Article
- Immune-related adverse events in patients with preexisting myasthenia gravis and thymoma following immune checkpoint inhibitor treatment: a retrospective, observational study.Frontiers in immunology · 2026Observational
- Investigating the Risk Factors for Medication Nonadherence in Myasthenia Gravis Patients: Establishing a Nomogram Model.Patient preference and adherence · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is the most common primary disorder of neuromuscular transmission, but the incidence of MG in China is unknown. We conducted the first nationwide study to determine the incidence and mortality rates of MG in all age groups at the national level in China.
methodsThis national population-based registry study is based on the database of the Hospital Quality Monitoring System of National Health Commission, which covers 1665 hospitals providing myasthenia gravis care in 31 provinces and municipalities across China. 94,638 hospital admissions for 59,243 myasthenia gravis patients were identified from January 1st, 2016 to December 31st, 2018. Myasthenia gravis was identified by ICD-10 codes (G70). Incidence of myasthenia gravis was stratified by age, sex, and province.
findingsOf 59,243 patients, 30,503 individuals with myasthenia gravis were newly diagnosed. Age and sex adjusted incidence of myasthenia gravis was 0.68 per 100,000 person-years, with highest in the age group of 70-74 years. The incidence in females was 0.76 per 100,000 and 0.60 per 100,000 in males. The admission mortality rate was 14.69‰. Respiratory failure was the leading cause of death in patients with myasthenic crisis. There were 14,840 patients with thymomas, encompassing 14,636 (26.5%) adults and 204 (7.1%) juveniles. 9453 (63.7%) patients with thymomas underwent thymomectomy. The median length of hospital stay was 8 days (interquartile range (IQR) 4 to 15 days) with median hospitalization cost $1037 (IQR $493 to $2925). The Basic Medical Insurance was the most common payment method, covering 67.4% of patients.
interpretationThe age and sex adjusted incidence of MG was 0.68 per 100,000 person-years in China. The admission mortality rate was 14.69‰. Most cases of new onset MG occurred in the seventh decade of life.
fundingNational Science Foundation of China (91642205, and 81830038); Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.